Low Energy Shockwave Therapy for Improving Erectile Dysfunction
NCT ID: NCT02304679
Last Updated: 2020-08-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
154 participants
INTERVENTIONAL
2015-07-01
2020-06-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Low Intensity Extracorporeal Shockwave Therapy for Patients With Erectile Dysfunction
NCT02005731
Safety and Efficacy Associated With Treating Erectile Dysfunction Patients With Low Intensity Shockwaves by Renova
NCT01811797
Safety and Efficacy of Low Intensity Shockwave for the Treatment of Erectile Dysfunction
NCT03067987
Low Intensity Shockwaves Therapy for the Treatment of Erectile Dysfunction. 12- Month Follow-Up
NCT03670628
Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT) by 'Renova' for Patients With Erectile Dysfunction
NCT01814852
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A. To evaluate erectile function (EF) categorical improvement in patients receiving 4 weekly treatments of shockwave therapy versus those receiving a sham treatment, at 3 months after a first sequence of treatment.
B. To compare improvements in erectile function between 4 weeks of phosphodiesterase type 5 inhibitor (PDE5i) use and 4 weekly treatments of shockwave therapy ("within patient" effect).
C. To compare improvements in erectile function between 4 weeks of PDE5 inhibitor use and 4 weekly treatments of sham shock wave therapy ("within patient" effect).
D. To evaluate the effect of a 2nd sequence of 4-8 weekly shock wave treatments 3 months after this second sequence.
E. To evaluate treatment effects (the same comparisons as in objectives A, B, C, D) on other validated measure of EF (question 2 of the sexual encounter profile (SEP2), question 3 of the sexual encounter profile (SEP3), Global Assessment Question (GAQ), Erection Hardness Scale (EHS)), and the remaining domains of the IIEF score (orgasmic function, sexual desire, intercourse satisfaction, overall satisfaction), as well as the total IIEF score.
F. To evaluate treatment tolerance and potential adverse events. G. To compare changes in EF measures over time for a follow-up period of 12 months following the second sequence of 4 weekly shock wave treatments.
H. To compare the effect of a sequence of 4 weekly shock wave treatments versus 8 biweekly shock wave treatments 3 months after the treatment ("within patient" effect).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LIESWT arm
Patients randomized to this arm will have two sequences of Low-Intensity Extracorporeal Shock Wave Therapy (LIESWT).
Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2.
Pre-inclusion questionnaires
(Month -2)
During this visit, the investigator will:
* Validate the patient's inclusion and exclusion criteria;
* Obtain informed consent from the patient;
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
* Prescribe 1 month of PDE5i treatment.
* The next visit will be scheduled
1 month of PDE5i treatment
5 mg Tadalafil per day for 1 month
PDE5i follow-up questionnaires
(Month -1)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
* Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).
* The next visit will be scheduled
Inclusion questionnaires
(Day 0)
During this visit the investigator will:
* Verify inclusion and exclusion criteria, and proceed with final inclusion
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
* Randomize the patient at the end of the visit
* The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit.
4 weekly LIESWT (Wave 1) with the RENOVA device
Following final inclusion, patients will have weekly LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
Follow-up questionnaires 1 month after Wave 1
(Month 2)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Follow-up questionnaires 3 months after Wave 1
(Month 4)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
* The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit.
8 bi-weekly LIESWT (Wave 2) with the RENOVA device
During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
Follow-up questionnaires 1 month after Wave 2
(Month 6)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Questionnaires via postal mail
Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
Final follow-up questionnaires 12 months after Wave 2
(Month 17)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Sham arm
Patients randomized to this arm will have one sequence of sham Low-Intensity Extracorporeal Shock Wave Therapy and then three months later one sequence of Low-Intensity Extracorporeal Shock Wave Therapy.
Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly sham LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2.
Pre-inclusion questionnaires
(Month -2)
During this visit, the investigator will:
* Validate the patient's inclusion and exclusion criteria;
* Obtain informed consent from the patient;
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
* Prescribe 1 month of PDE5i treatment.
* The next visit will be scheduled
1 month of PDE5i treatment
5 mg Tadalafil per day for 1 month
PDE5i follow-up questionnaires
(Month -1)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
* Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).
* The next visit will be scheduled
Inclusion questionnaires
(Day 0)
During this visit the investigator will:
* Verify inclusion and exclusion criteria, and proceed with final inclusion
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
* Randomize the patient at the end of the visit
* The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit.
4 weekly sham LIESWT (Wave 1) with the RENOVA device
Following final inclusion, patients will have weekly sham LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
Follow-up questionnaires 1 month after Wave 1
(Month 2)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Follow-up questionnaires 3 months after Wave 1
(Month 4)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
* The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit.
8 bi-weekly LIESWT (Wave 2) with the RENOVA device
During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
Follow-up questionnaires 1 month after Wave 2
(Month 6)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Questionnaires via postal mail
Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
Final follow-up questionnaires 12 months after Wave 2
(Month 17)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pre-inclusion questionnaires
(Month -2)
During this visit, the investigator will:
* Validate the patient's inclusion and exclusion criteria;
* Obtain informed consent from the patient;
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
* Prescribe 1 month of PDE5i treatment.
* The next visit will be scheduled
1 month of PDE5i treatment
5 mg Tadalafil per day for 1 month
PDE5i follow-up questionnaires
(Month -1)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
* Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).
* The next visit will be scheduled
Inclusion questionnaires
(Day 0)
During this visit the investigator will:
* Verify inclusion and exclusion criteria, and proceed with final inclusion
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
* Randomize the patient at the end of the visit
* The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit.
4 weekly LIESWT (Wave 1) with the RENOVA device
Following final inclusion, patients will have weekly LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
4 weekly sham LIESWT (Wave 1) with the RENOVA device
Following final inclusion, patients will have weekly sham LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
Follow-up questionnaires 1 month after Wave 1
(Month 2)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Follow-up questionnaires 3 months after Wave 1
(Month 4)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
* The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit.
8 bi-weekly LIESWT (Wave 2) with the RENOVA device
During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
Follow-up questionnaires 1 month after Wave 2
(Month 6)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Questionnaires via postal mail
Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
Final follow-up questionnaires 12 months after Wave 2
(Month 17)
During this visit the investigator will:
* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient must have given his informed and signed consent.
* The patient must be insured or beneficiary of a health insurance plan.
* The patient is a man between 18 and 80 years of age. (≥18 years and \< 80 years)
* The patient has been in a stable sexual relationship for over 3 months
* The patient is consulting for erectile dysfunction lasting for over 6 months
* IIEF-EF6 score between 6 and 25
* Patients have at least a natural tumescence during sexual stimulation (EHS score ≥ 1)
* Pre-inclusion: Patient is willing to have 4 weeks of PDE5i treatment at the beginning of the trial, and then stop all treatment for an additional month.
* Pre-inclusion: The patient agrees to try to engage at least 3 sexual intercourses per month during this period
* Inclusion: Patient has completed 4 weeks of PDE5i treatment, and then stopped all treatment for an additional month.
* Patient is available for a follow up of 19 months (at time of pre-inclusion and then 17 months at time of inclusion)
Exclusion Criteria
* Within the past three months, the patient has participated in another interventional study
* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection
* The patient is an adult under guardianship
* The patient refuses to sign the consent
* It is impossible to correctly inform the patient
* Complete anerection
* History of pelvic cancer surgery (radical prostatectomy, cystectomy, abdominoperineal resection of the rectum)
* Untreated testosterone deficiency
* Neurological disease affecting the central nervous system
* Untreated psychiatric disease, or psychiatric disease that may compromise study participation
* Anatomical malformation of the penis considered by the investigator as being able to prevent vaginal penetration
* Chronic haematological pathology associated with risk of haemorrhage
* Oral or injectable antiandrogen treatment
* The patient is taking blood thinners AND/OR has an International Normalized Ratio \>3
* Known allergy to treatments used in the study (e.g. Cialis, gel)
* Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the SPC.
* In clinical studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway. Therefore, administration of CIALIS to patients who are using any form of organic nitrate is contraindicated. (see section 4.5 of the SPC).
* CIALIS, must not be used in men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease.
* The following groups of patients with cardiovascular disease were not included in clinical trials and the use of tadalafil is therefore contraindicated:
* patients with myocardial infarction within the last 90 days,
* patients with unstable angina or angina occurring during sexual intercourse,
* patients with New York Heart Association Class 2 or greater heart failure in the last 6 months,
* patients with uncontrolled arrhythmias, hypotension (\< 90/50 mm Hg), or uncontrolled
* uncontrolled hypertension,
* patients with a stroke within the last 6 months.
* CIALIS is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4 of the SPC).
18 Years
79 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stéphane Droupy, MD, PhD
Role: STUDY_DIRECTOR
Centre Hospitalier Universitaire de Nîmes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Bordeax - Hôpital Pellegrin
Bordeaux, , France
APHP - Hôpital Raymond-Poincaré
Garches, , France
Clinique Beau Soleil
Montpellier, , France
CHRU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, , France
CHU de Lyon - Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-A00486-41
Identifier Type: OTHER
Identifier Source: secondary_id
PHRC-N/2013/SD-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.